Is there a role of Gabapentin as Monotherapy in Dystonic Cerebral Palsy?

Is there a role of Gabapentin in Dystonic Cerebral Palsy?

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/11/016262

Enrollment

Registered

2018-11-02

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G808- Other cerebral palsy Health Condition 2: G808- Other cerebral palsy

Interventions

Intervention1: Gabapentin: Gabapentin,is an analogue of gamma-aminobutyric acid but neither acts as a GABA agonist or antagonist. Mechanisms of action of gabapentin are largely unknown. Gabapentinoid

Eligibility

Inclusion criteria

Inclusion criteria: 1) Diagnosed case of dystonic cerebral palsy 2) Participants not on any medication for tone for last 4 weeks 3) Participants on stable rehabilitation programme for last 6 weeks 4) Participants are able to swallow the drug 5) Parents/ caregivers are able to understand/comply with the study trial requirements

Exclusion criteria

Exclusion criteria: 1) Known allergy to Gabapentin and/or its ingredients 2) Age less than 2 years and greater than 18 years at the enrollment

Design outcomes

Primary

Measure	Time frame
Barry Albright Dystonia Scale Movement Disorder- Childhood Rating ScaleTimepoint: Day 0, 12 weeks and 24 weeks	—

Secondary

Measure	Time frame
Monitoring side effectsTimepoint: 4 weeks, 12 weeks and 24 weeks;PEDsQLTimepoint: Day 0, 12 weeks and 24 weeks	—

Countries

India

Contacts

Public ContactDr Anaita Udwadia Hegde

Jaslok Hospital and Research Center

anaitahegde@gmail.com9820186155

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026